Pfizer denies Neurontin data was "manipulated"

USA-based global pharmaceutical behemoth Pfizer has denied allegations reported in the New York Times, which state that the publication of scientific studies to support the use in other indications of its epilepsy therapy Neurontin (gabapentin), was "manipulated" by the drug major, while other negative data were suppressed. However, Pfizer also told the NYT that it had introduced new procedures after buying Neurontin's developer, Warner-Lambert in 2000.

Testimony by Kay Dickersin, from Johns Hopkins Bloomberg School of Public Health and one of the experts who examined documents from 21 studies as part of an earlier law suit in Boston, was unsealed this month. All five positive trials were fully reported, but only six negative ones, two of which were in abbreviated form, she claimed.